Drugs / pegylated interferon-α2a
pegylated interferon-α2a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01399619 | Sep 2011 → Sep 2013 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02890368 Background | Sep 2016 → Mar 2020 | breast carcinoma, cutaneous neuroendocrine carcinoma, melanoma, mycosis fungoides +2 | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT01220596 Comparator | Jun 2010 → Jun 2013 | chronic hepatitis B virus infection | Hanyang University | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated interferon α-2a | “Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.” PMID 25710287 ↗ Mar 2015 |
| Known as | Generic/Brand name: Pegylated interferon α-2a/Pegasys(TM) | “Generic/Brand name: Pegylated interferon α-2a/Pegasys(TM)” NCT01220596 ↗ |
| Known as | Peg-INF | “various types of combined therapy with nucleotide analogs and pegylated interferon (Peg-INF) in patients with hepatitis B patients have been tried.” PMID 29998882 ↗ Jul 2018 |
| Route | Subcutaneous | “Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection” NCT01220596 ↗ |